Radiotherapy for ductal carcinoma of the prostate: an analysis based on the Japanese radiation oncology study group survey. (6th December 2022)

• Record Type: Journal Article
• Authors: Kawamura, Hidemasa; Nakamura, Katsumasa; Yoshioka, Yasuo; Itasaka, Satoshi; Tomita, Natsuo; Onishi, Masahiro; Iwata, Hiromitsu; Aizawa, Takuya; Kikuchi, Koyo; Nagata, Kenji; Nakamura, Kiyonao; Nishioka, Kentaro; Ishiyama, Hiromichi; Ueno, Shuichi; Kokubo, Masaki; Yamazaki, Hideya; Watanabe, Kenta; Toyoda, Tatsuya; Akimoto, Tetsuo
• Is Part Of: Japanese journal of clinical oncology. Volume 53:Number 2(2023)
• Page Start: 146
• Page End: 152
• Publication Date: 2022-12-06
• Subjects: prostate cancer -- ductal carcinoma -- radiation therapy; Oncology -- Periodicals; Cancer -- Periodicals; 616.994005
• DOI: 10.1093/jjco/hyac180
• Languages: English
• ISSNs: 0368-2811

Abstract

Abstract: Background: The clinical characteristics of prostate ductal carcinoma is still unclear, and treatment strategy has not yet been established due to its rarity. Therefore, we conducted a multicenter survey of radiation therapy for prostate ductal carcinoma in Japan. Method: Data of patients with ductal carcinoma of the prostate treated with radiation therapy between 1996 and 2018 were extracted from the database of each facility. Results: Fifty-two treatment records of 41 patients were collected from nine institutions. The treatment purpose and situations were varied curative intent to palliation. Twenty-eight patients received curative treatments. The median follow-up period of these patients was 68 months. Androgen deprivation therapy was combined with radiation therapy in 26 cases (93%). X-ray and particle irradiation was used. Radiation dose range was 63–78 Gy; 5-year overall survival, progression-free survival and biochemical relapse-free survival were 87.0, 79.3 and 79.3%, respectively. One patient experienced Grade 3 radiation proctitis and one experienced Grade 3 radiation cystitis. There were no Grade 4 or worse adverse events. Conclusion: Most patient received similar treatment with adenocarcinoma of prostate, and the clinical results were compatible. For more reliable evidence, further studies are required. Abstract : This is the first study to report the results of a nationwide survey in Japan analyzing ductal carcinoma of the prostate treated with radiotherapy.